Active, not recruitingPhase 2NCT07108153
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sionna Therapeutics Inc.
- Principal Investigator
- Medical DirectorSionna Therapeutics Inc.
- Intervention
- SION-719(drug)
- Enrollment
- 16 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2025 – 2026
Study locations (13)
- National Jewish Health, Denver, Colorado, United States
- University of Iowa, Iowa City, Iowa, United States
- Johns Hopkins, Baltimore, Maryland, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Washington University, St Louis, Missouri, United States
- New York Medical College, Hawthorne, New York, United States
- Columbia University, New York, New York, United States
- University Hospital of Cleveland, Cleveland, Ohio, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- University of Washington, Seattle, Washington, United States
- Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
- Gold Coast University Hospital, Southport, Queensland, Australia
- Monash University, Melbourne, Victoria, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07108153 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS